After the Pandemic, Antibody R&D Remains Key
Date: August 26, 2021
Time: 2:00PM EDT
Abstract: The onslaught of a global pandemic triggered a frenzy of R&D activity in the industry. But where we saw a revolution in vaccine development in record time, finding new drugs to effectively fight the virus remained difficult and fraught with failure and half-measures of success. Nevertheless, a group of players is still actively engaged in developing a new generation of antibodies to fight this virus, and others to come. We’ll talk to the key leaders in the field about where this is headed, and how it may more broadly affect everyone doing antibody work.
Victor Vinci, Ph.D.
Vice President, Product Development